Summary
A rapid and sensitive assay was developed for the measurement of plasma concentrations of zileuton racemate, a potent inhibitor of 5-lipoxygenase. Zileuton and its inactive Af-dehydroxylated metabolite were extracted from human, monkey, and rat plasma by use of a solid-phase extraction column (Analytichem Bond Elut®). The compounds were then separated by reverse-phase high performance liquid chromatography (HPLC) on a Supelcosil LC-18 column and quantified on the basis of ultraviolet absorption at 260nm relative to an internal standard. The extraction recovery of zileuton, as determined by HPLC assay, was 77.9 ± 1.7%. Recovery of the metabolite was 85.8 ± 0.7%. Calibration curves for both compounds were linear over the zileuton concentration range 0.01 to 10.0 mg/L (correlation coefficients > 0.987), while the intra- and interassay coefficients of variation were < 15.6%. In practice, > 97% of blinded daily spiked control samples for zileuton and > 90% of those for the metabolite were within 10% of their target concentrations.
Similar content being viewed by others
References
Piper PJ. Formation and actions of leukotrienes. Physiological Reviews 1984; 64: 744–61
Samuelsson B. Leukotrienes: mediators of immediate hypersensitivity reactions and inflammation. Science 1983; 220: 568–75
Carter GW, Young PR, Albert DH, et al. A new potent orally active 5-lipoxygenäse inhibitor. In: Zor et al., editors. A-64077, leukotrienes and prostanoids in health and disease. New trends in lipid mediator research. Basel: Karger, 1989; 3: 50–5
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Granneman, G.R., Braeckman, R.A. & Erdman, K.A. Determination of a New 5-Lipoxygenase Inhibitor, Zileuton, and its Inactive N-Dehydroxylated Metabolite in Plasma by High Performance Liquid Chromatography. Clin-Pharmacokinet 29 (Suppl 2), 1–8 (1995). https://doi.org/10.2165/00003088-199500292-00003
Published:
Issue Date:
DOI: https://doi.org/10.2165/00003088-199500292-00003